Stratos Wealth Advisors LLC Sells 67 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Stratos Wealth Advisors LLC decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,581 shares of the biopharmaceutical company’s stock after selling 67 shares during the quarter. Stratos Wealth Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $6,113,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Paragon Capital Management Inc. acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $1,257,000. 1858 Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $224,000. Avitas Wealth Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 12.7% during the 4th quarter. Avitas Wealth Management LLC now owns 372 shares of the biopharmaceutical company’s stock worth $265,000 after buying an additional 42 shares during the last quarter. Redwood Wealth Management Group LLC lifted its stake in shares of Regeneron Pharmaceuticals by 4.2% during the 4th quarter. Redwood Wealth Management Group LLC now owns 497 shares of the biopharmaceutical company’s stock worth $354,000 after buying an additional 20 shares during the last quarter. Finally, Ninety One UK Ltd lifted its stake in shares of Regeneron Pharmaceuticals by 14.4% during the 4th quarter. Ninety One UK Ltd now owns 78,005 shares of the biopharmaceutical company’s stock worth $55,565,000 after buying an additional 9,820 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on REGN. Citigroup dropped their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Truist Financial reduced their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. Bernstein Bank reduced their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday. Royal Bank of Canada reduced their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Finally, Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $983.65.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $697.05 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20. The firm has a 50 day moving average of $719.16 and a 200 day moving average of $918.90. The company has a market capitalization of $76.60 billion, a price-to-earnings ratio of 17.25, a price-to-earnings-growth ratio of 1.60 and a beta of 0.08. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the company posted $11.86 earnings per share. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.75 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.50%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.